MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DE CLERCQ, E.
Right arrow Articles by TORRENCE, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DE CLERCQ, E.
Right arrow Articles by TORRENCE, P. F.

Molecular Pharmacology, Vol 14, 422-430, Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics

5-Nitro-2'-deoxyuridine and 5-Nitro-2'-deoxyuridine 5'-Monophosphate: Antiviral Activity and Inhibition of Thymidylate Synthetase in Vivo

ERIK DE CLERCQ 1, JOHAN DESCAMPS 1, GUANG-FU HUANG 2, and PAUL F. TORRENCE 2

1 Rega Institute for Medical Research, University of Leuven, B-3000 Leuven, Belgium
2 Laboratory of Chemistry, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014

The antiviral activity of a series of nitrated uracil derivatives, including 5-nitrouracil, 1-methyl-5-nitrouracil, 1,3-dimethyl-5-nitrouracil, 5-nitro-2'-deoxyuridine (5-nitro-dU), 3'-O,5-dinitro-2'-deoxyuridine, 5-nitro-2'-deoxyuridine 5'-monophosphate (5-nitro-dUMP), and 3'-O,5-dinitro-2'-deoxyuridine 5'-monophosphate, was evaluated in primary rabbit kidney or human skin fibroblast cultures challenged with vaccinia, herpes simplex, or vesicular stomatitis virus. The most remarkable antiviral activity was shown by 5-nitro-dU and 5-nitro-dUMP, which inhibited the replication of vaccinia virus at concentrations as low as 0.1-0.4 µg/ml. Somewhat higher concentrations were required to inhibit the replication of herpes simplex virus (1-4 µg/ml for 5-nitro-dU and 40-100 µg/ml for 5-nitro-dUMP). Neither 5-nitro-dU nor its 5'-monophosphate was inhibitory to vesicular stomatitis virus at concentrations up to 100 µg/ml. Combination of 5-nitro-dU with 5-iodo-2'-deoxyuridine (5-iodo-dU) resulted in an increased antiviral activity over the activity of the compounds used individually, suggesting that 5-nitro-dU and 5-iodo-dU act at different steps in DNA biosynthesis. In fact, 5-nitro-dU and its 5'-monophosphate effectively blocked the incorporation of [14C]2'-deoxyuridine into host cell DNA, but neither compound inhibited the incorporation of [3H]2'-deoxythymidine, pointing to thymidylate synthetase as a specific target for the action of 5-nitro-dU (or 5-nitro-dUMP). Inhibition of thymidylate synthetase would account for the antiviral activity of 5-nitro-dU, since the inhibitory effect of 5-nitro-dU on vacciia virus replication could be readily reversed by 2'-deoxythymidine, but not by 2'-deoxyuridine or 2'-deoxycytidine. Other deoxythymidine analogues that were found to inhibit deoxyuridine incorporation, but not deoxythymidine incorporation, and could therefore be assumed to block thymidylate synthetase selectively in vivo, include 5-fluoro-, 5-trifluoromethyl-, 5-cyamo-, and 5-thiocyamato-2'-deoxyuridine.

Submitted on September 6, 1977
Accepted on January 5, 1978







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics